Log in

NYSE:AGN - Allergan Stock Price, Forecast & News

$173.00
-2.54 (-1.45 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$170.96
Now: $173.00
$176.59
50-Day Range
$164.70
MA: $188.63
$202.10
52-Week Range
$114.27
Now: $173.00
$202.21
Volume3.42 million shs
Average Volume5.41 million shs
Market Capitalization$56.92 billion
P/E RatioN/A
Dividend Yield1.69%
Beta1.47
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Read More
Allergan logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP01849010
Phone862-261-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.09 billion
Cash Flow$36.19 per share
Book Value$177.28 per share

Profitability

Net Income$-5,271,000,000.00

Miscellaneous

Employees17,400
Market Cap$56.92 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive AGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGN and its competitors with MarketBeat's FREE daily newsletter.


Allergan (NYSE:AGN) Frequently Asked Questions

How has Allergan's stock been impacted by COVID-19 (Coronavirus)?

Allergan's stock was trading at $185.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AGN shares have decreased by 6.7% and is now trading at $173.00. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Allergan?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 13 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allergan.

When is Allergan's next earnings date?

Allergan is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Allergan.

How were Allergan's earnings last quarter?

Allergan plc (NYSE:AGN) issued its earnings results on Monday, February, 10th. The company reported $5.22 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $4.57 by $0.65. The business earned $4.35 billion during the quarter, compared to analysts' expectations of $4.09 billion. Allergan had a negative net margin of 32.76% and a positive return on equity of 9.82%. The company's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.29 EPS. View Allergan's earnings history.

How often does Allergan pay dividends? What is the dividend yield for Allergan?

Allergan announced a quarterly dividend on Wednesday, March 18th. Shareholders of record on Thursday, April 16th will be given a dividend of $0.74 per share on Monday, June 15th. This represents a $2.96 annualized dividend and a yield of 1.71%. The ex-dividend date is Wednesday, April 15th. View Allergan's dividend history.

How will Allergan's stock buyback program work?

Allergan declared that its Board of Directors has approved a stock repurchase plan on Tuesday, January 29th 2019, which authorizes the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire up to 4.1% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's board believes its stock is undervalued.

What price target have analysts set for AGN?

15 equities research analysts have issued twelve-month price targets for Allergan's stock. Their forecasts range from $144.95 to $203.00. On average, they expect Allergan's stock price to reach $180.08 in the next year. This suggests a possible upside of 4.1% from the stock's current price. View analysts' price targets for Allergan.

Has Allergan been receiving favorable news coverage?

Media coverage about AGN stock has trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Allergan earned a news impact score of -1.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutAllergan.

Are investors shorting Allergan?

Allergan saw a decline in short interest during the month of February. As of February 14th, there was short interest totaling 13,700,000 shares, a decline of 11.0% from the January 30th total of 15,400,000 shares. Based on an average daily trading volume, of 2,390,000 shares, the short-interest ratio is presently 5.7 days. Currently, 4.2% of the shares of the company are short sold. View Allergan's Current Options Chain.

Who are some of Allergan's key competitors?

What other stocks do shareholders of Allergan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Who are Allergan's key executives?

Allergan's management team includes the following people:
  • Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 49)
  • Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 51)
  • Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 64)
  • Mr. Matthew M. Walsh, Exec. VP & CFO (Age 52)
  • Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 51)

What is Allergan's stock symbol?

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Who are Allergan's major shareholders?

Allergan's stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (4.39%), Franklin Resources Inc. (2.24%), Longview Partners Guernsey LTD (2.10%), Renaissance Technologies LLC (1.53%), Geode Capital Management LLC (1.45%) and Norges Bank (1.19%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Matthew M Walsh and William Meury. View institutional ownership trends for Allergan.

Which institutional investors are selling Allergan stock?

AGN stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Assenagon Asset Management S.A., Fred Alger Management LLC, MUFG Securities EMEA plc, State Street Corp, Janus Henderson Group PLC, FMR LLC, and Nuveen Asset Management LLC. View insider buying and selling activity for Allergan.

Which institutional investors are buying Allergan stock?

AGN stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Renaissance Technologies LLC, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Segantii Capital Management Ltd, Bank of Montreal Can, Beryl Capital Management LLC, Laurion Capital Management LP, and FIL Ltd. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, and Matthew M Walsh. View insider buying and selling activity for Allergan.

How do I buy shares of Allergan?

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Allergan's stock price today?

One share of AGN stock can currently be purchased for approximately $173.00.

How big of a company is Allergan?

Allergan has a market capitalization of $56.92 billion and generates $16.09 billion in revenue each year. The company earns $-5,271,000,000.00 in net income (profit) each year or $17.64 on an earnings per share basis. Allergan employs 17,400 workers across the globe. View additional information about Allergan.

What is Allergan's official website?

The official website for Allergan is http://www.allergan.com/.

How can I contact Allergan?

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]


MarketBeat Community Rating for Allergan (NYSE AGN)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  1,378 (Vote Outperform)
Underperform Votes:  693 (Vote Underperform)
Total Votes:  2,071
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: What is cost of equity?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel